Atherosclerosis
Volume 208, Issue 1 , Pages 19-25 , January 2010

The potential protective effects of taurine on coronary heart disease

  • Oktawia P. Wójcik

      Affiliations

    • Department of Environmental Medicine, New York University School of Medicine, New York, NY 10016, USA
    • ,
  • Karen L. Koenig

      Affiliations

    • Department of Environmental Medicine, New York University School of Medicine, New York, NY 10016, USA
    • ,
  • Anne Zeleniuch-Jacquotte

      Affiliations

    • Department of Environmental Medicine, New York University School of Medicine, New York, NY 10016, USA
    • New York University Cancer Institute, New York University School of Medicine, New York, NY 10016, USA
    • ,
  • Max Costa

      Affiliations

    • Department of Environmental Medicine, New York University School of Medicine, New York, NY 10016, USA
    • New York University Cancer Institute, New York University School of Medicine, New York, NY 10016, USA
    • Department of Pharmacology, New York University School of Medicine, New York, NY 10016, USA
    • ,
  • Yu Chen

      Affiliations

    • Department of Environmental Medicine, New York University School of Medicine, New York, NY 10016, USA
    • New York University Cancer Institute, New York University School of Medicine, New York, NY 10016, USA
    • Corresponding Author InformationCorresponding author at: New York University School of Medicine, 650 First Avenue, 5th Floor, Room 510, New York, NY 10016-3240, USA. Tel.: +1 212 263 4839; fax: +1 212 263 8570.

Received 17 October 2008 ,Revised 29 May 2009 ,Accepted 2 June 2009.

References 

  1. AHA . Heart disease and stroke statistics—2008 update at a glance. Dallas, Texas: American Heart Association; 2008;p. 1–43
  2. Birdsall TC. Therapeutic applications of taurine. Alt Med Rev. 1998;3:128–136
  3. Huxtable RJ. Expanding the circle 1975–1999: sulfur biochemistry and insights on the biological functions of taurine. Adv Exp Med Biol. 2000;483:1–25
  4. Schuller-Levis G, Park E. Is taurine a biomarker?. Adv Clin Chem. 2006;41:1–21
  5. O’Flaherty L, Stapleton PP, Redmond HP, Bouchier-Hayes DJ. Intestinal taurine transport: a review. Eur J Clin Invest. 1997;27:873–880
  6. Tappaz ML. Taurine biosynthetic enzymes and taurine transporter: molecular identification and regulations. Neurochem Res. 2004;29:83–96
  7. Stapleton PP, Charles RP, Redmond HP, Bouchier-Hayes DJ. Taurine and human nutrition. Clin Nutr. 1997;26:103–108
  8. Finnegan D. The health effects of stimulant drinks. Br Nutr Foundation Nutr Bull. 2003;28:147–155
  9. Paauw JD, Davis AT. Taurine supplementation at three different dosages and its effects on trauma patients. Am J Clin Nutr. 1994;60:203–206
  10. Yamori Y, Murakami S, Ikeda K, Nara Y. Fish and lifestyle-related disease prevention: experimental and epidemiological evidence for anti-atherogenic potential of taurine. Clin Exp Pharmacol Physiol Suppl. 2004;31:S20–S23
  11. Lam NV, Chen W, Suruga K, Nishimura N, Goda T, Yokogoshi H. Enhancing effect of taurine on CYP7A1 mRNA expression in Hep G2 cells. Amino Acids. 2006;30:43–48
  12. Yokogoshi H, Mochizuki H, Nanami K, Hida Y, Miyachi F, Oda H. Dietary taurine enhances cholesterol degradation and reduces serum and liver cholesterol concentrations in rats fed a high-cholesterol diet. J Nutr. 1999;129:1705–1712
  13. Murakami S, Kondo Y, Toda Y, et al. Effect of taurine on cholesterol metabolism in hamsters: up-regulation of low density lipoprotein (LDL) receptor by taurine. Life Sci. 2002;70:2355–2366
  14. Chen W, Matuda K, Nishimura N, Yokogoshi H. The effect of taurine on cholesterol degradation in mice fed a high-cholesterol diet. Life Sci. 2004;74:1889–1898
  15. Mizushima S, Nara Y, Sawamura M, Yamori Y. Effects of oral taurine supplementation on lipids and sympathetic nerve tone. Adv Exp Med Biol. 1996;403:615–622
  16. Zhang M, Bi L, Fang JH, et al. Beneficial effects of taurine on serum lipids in overweight or obese non-diabetic subjects. Amino Acids. 2004;26:267–271
  17. Schaffer SW, Lombardini JB, Azuma J. Interaction between the actions of taurine and angiotensin II. Amino Acids. 2000;18:305–318
  18. Kohashi N, Okabayashi Y, Hama J, Katori R. Decreased urinary taurine in essential hypertension. Prog Clin Biol Res. 1983;125:73–87
  19. Yamamoto J, Akabane S, Yoshimi H, Nakai M, Ikeda M. Effects of taurine on stress-evoked hemodynamic and plasma catecholamine changes in spontaneously hypertensive rats. Hypertension. 1985;7:913–922
  20. Fujita T, Sato Y. Hypotensive effect of taurine. Possible involvement of the sympathetic nervous system and endogenous opiates. J Clin Invest. 1988;82:993–997
  21. Ideishi M, Miura S, Sakai T, Sasaguri M, Misumi Y, Arakawa K. Taurine amplifies renal kallikrein and prevents salt-induced hypertension in Dahl rats. J Hypertens. 1994;12:653–661
  22. Militante JD, Lombardini JB. Treatment of hypertension with oral taurine: experimental and clinical studies. Amino Acids. 2002;23:381–393
  23. Anuradha CV, Balakrishnan SD. Taurine attenuates hypertension and improves insulin sensitivity in the fructose-fed rat, an animal model of insulin resistance. Can J Physiol Pharmacol. 1999;77:749–754
  24. Nara Y, Yamori Y, Lovenberg W. Effect of dietary taurine on blood pressure in spontaneously hypertensive rats. Biochem Pharmacol. 1978;27:2689–2692
  25. Liu L, Liu L, Ding J, et al. Ethnic and environmental differences in various markers of dietary intake and blood pressure among Chinese Han and three other minority peoples of China: results from the WHO cardiovascular diseases and alimentary comparison (CARDIAC) study. Hepertens Res. 2001;24:315–322
  26. Mizushima S, Moriguchi EH, Ishikawa P, et al. Fish intake and cardiovascular risk among middle-aged Japanese in Japan and Brazil. J Cardiovasc Risk. 1997;4:191–199
  27. Fujita T, Katsuyuki A, Noda H, Yasushi I, Sato Y. Effects of increased adrenomedullary activity and taurine in young patients with borderline hypertension. Circulation. 1987;75:525–532
  28. Sethupathy S, Elanchezhiyan C, Vasudevan K, Rajagopal G. Antiatherogenic effect of taurine in high fat diet fed rats. Indian J Exp Biol. 2002;40:1169–1172
  29. Kondo Y, Toda Y, Kitajima H, et al. Taurine inhibits development of atherosclerotic lesions in apolipoprotein E-deficient mice. Clin Exp Pharmacol Physiol. 2001;28:809–815
  30. Marcinkiewicz J, Grabowska A, Bereta J, Bryniarski K, Nowak B. Taurine chloramine down-regulates the generation of murine neutrophil inflammatory mediators. Immunopharmacology. 1998;40:27–38
  31. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;326:801–809
  32. Casey RG, Gang C, Joyce M, Bouchier-Hayes DJ. Taurine attenuates acute hyperglycaemia-induced endothelial cell apoptosis, leucocyte–endothelial cell interactions and cardiac dysfunction. J Vasc Res. 2007;44:31–39
  33. Bedrosian I, Duane Sofia R, Wolff SM, Dinarello CA. Tauroline, an analogue of the amino acid taurine, suppresses interleukin 1 and tumor necrosis factor synthesis in human peripheral blood mononuclear cells. Cytokine. 1991;3:568–575
  34. Park E, Quinn MR, Wright CE, Schuller-Levis G. Taurine chloramine inhibits the synthesis of nitric oxide and the release of tumor necrosis factor in activated RAW 264.7 cells. J Leukoc Biol. 1993;54:119–124
  35. Milei J, Ferreira R, Llesuy S, Forcada P, Covarrubias J, Boveris A. Reduction of reperfusion injury with preoperative rapid intravenous infusion of taurine during myocardial revascularization. Am Heart J. 1992;123:339–345
  36. Yamori Y, Liu L, Ikeda K, et al. Distribution of twenty-four hour urinary taurine excretion and association with ischemic heart disease mortality in 24 populations of 16 countries: results from the WHO-CARDIAC Study. Hypertens Res. 2001;24:453–457
  37. Yamori Y, Liu L, Mizushima S, Ikeda K, Nara Y. Male cardiovascular mortality and dietary markers in 25 population samples of 16 countries. J Hypertens. 2006;24:1499–1505
  38. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903–1913
  39. Shao A, Hathcock JN. Risk assessment for the amino acids taurine, l-glutamine and l-arginine. Regul Toxicol Pharmacol. 2008;50:376–399
  40. Sturman JA, Rassin DK, Gaull G. Taurine in the development of the central nervous system. In:  Babeau A,  Huxtable RJ editor. Taurine and neurological disorders. New York: Raven; 1978;p. 47–91
  41. Hayes KC, Sturman JA. Taurine in metabolism. Annu Rev. 1981;1:401–425
  42. Sole MJ, Jeejeebhoy KN. Conditioned nutritional requirements and the pathogenesis and treatment of myocardial failure. Curr Opin Clin Nutr Metab Care. 2000;3:417–424
  43. Hansen SH. The role of taurine in diabetes and the development of diabetic complications. Diabetes Metab Res Rev. 2001;17:330–346
  44. Learn DB, Fried VA, Thomas EL. Taurine and hypotaurine content of human leukocytes. J Leukoc Biol. 1990;48:174–182
  45. Brosnan JT, Brosnan ME. The sulfur-containing amino acids: an overview. J Nutr. 2006;136:p. S1636–S1640
  46. Spaeth DG, Schneider DL, Sarett HP. Taurine synthesis, concentration, and bile salt conjugation in rat, guinea pig, and rabbit. Proc Soc Exp Biol Med. 1974;147:855–858
  47. Huxtable RJ. Physiological actions of taurine. Physiol Rev. 1992;72:101–163
  48. Laidlaw SA, Grosvenor M, Kopple JD. The taurine content of common foodstuffs. J Parenter Enteral Nutr. 1990;14:183–188
  49. Pasantes-Morales H, Quesada O, Alcocer L, Sãnchez Olea R. Taurine content in foods. Nutr Rep Int. 1989;40:793–801
  50. Lourenço R, Camilo ME. Taurine: a conditionally essential amino acid in humans? An overview in health and disease. Nutr Hosp. 2002;17:262–270

☆ This research was supported by U.S. grants: NIH grants ES000260, CA16087, CA098661 and American Heart Association grant 0835569D.

PII: S0021-9150(09)00432-8

doi: 10.1016/j.atherosclerosis.2009.06.002

Atherosclerosis
Volume 208, Issue 1 , Pages 19-25 , January 2010

Article Tools

* Image Usage & Resolution